The INNOVA project aims to create an advanced multidisciplinary diagnostic platform to support the Italian healthcare system and translational research. In this context, WP7, coordinated by the Pascale Institute and the focus of this study protocol, is responsible for developing a national platform for the multi-omic profiling of cancer patients eligible for precision medicine treatments, with the goal of supporting clinical decision-making.
Consent to participate in the study
Age >18 years
Performance status (PS) 0-1
Availability of biological samples for multi-omic profiling
Previous line of immunotherapy or targeted therapy
Previous radiotherapy at the sites of the most recent diagnostic biopsy
Most recent diagnostic biopsy performed >24 months before enrollment
Absence of measurable lesions
Oncologic patients eligible for targeted therapy and/or immunotherapy.
Cohort
Other
Multi-omic approach to cancer diagnosis.
Other interventionTo assess the impact of intratumoral heterogeneity on the effectiveness of targeted therapies and immunotherapy.
Disease progression
Rate of metastatic patients with disease progression (PD) within 3 months from the start of targeted therapy and/or immunotherapy, or disease recurrence rate at 6 months in patients undergoing adjuvant therapy.
Click on the lead sponsor to view all of their trials.
